Cerus Co. (NASDAQ:CERS) CEO Sells $103,074.70 in Stock

Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 71,086 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $1.45, for a total value of $103,074.70. Following the completion of the sale, the chief executive officer now directly owns 4,238,672 shares in the company, valued at approximately $6,146,074.40. The trade was a 1.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

William Mariner Greenman also recently made the following trade(s):

• On Friday, March 7th, William Mariner Greenman sold 60,984 shares of Cerus stock. The shares were sold at an average price of $1.50, for a total value of $91,476.00.
• On Tuesday, March 4th, William Mariner Greenman sold 23,023 shares of Cerus stock. The shares were sold at an average price of $1.55, for a total value of $35,685.65.

Cerus Trading Up 7.0 %

Shares of Cerus stock opened at $1.53 on Thursday. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.54. The firm has a market cap of $284.26 million, a PE ratio of -13.91 and a beta of 1.56. The business’s fifty day moving average is $1.71 and its two-hundred day moving average is $1.75. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The company had revenue of $50.81 million for the quarter, compared to analyst estimates of $50.81 million. Analysts anticipate that Cerus Co. will post -0.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.00 target price on shares of Cerus in a research note on Friday, February 21st.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. ARK Investment Management LLC raised its position in shares of Cerus by 14.2% in the 4th quarter. ARK Investment Management LLC now owns 20,814,752 shares of the biotechnology company’s stock worth $32,055,000 after buying an additional 2,589,721 shares during the period. Wasatch Advisors LP raised its position in shares of Cerus by 13.6% in the 4th quarter. Wasatch Advisors LP now owns 8,319,841 shares of the biotechnology company’s stock worth $12,813,000 after buying an additional 994,007 shares during the period. Senvest Management LLC raised its position in shares of Cerus by 6.5% in the 4th quarter. Senvest Management LLC now owns 6,393,979 shares of the biotechnology company’s stock worth $9,847,000 after buying an additional 387,603 shares during the period. Geode Capital Management LLC raised its position in shares of Cerus by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,454,525 shares of the biotechnology company’s stock worth $6,862,000 after buying an additional 39,072 shares during the period. Finally, State Street Corp raised its position in shares of Cerus by 2.2% in the 3rd quarter. State Street Corp now owns 3,738,893 shares of the biotechnology company’s stock worth $6,506,000 after buying an additional 79,505 shares during the period. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.